Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|M2698||MSC2363318A|M-2698||Akt Inhibitor (Pan) 21 S6 Kinase Inhibitor 5||M2698 (MSC2363318A) binds to and inhibits the activity of P70S6K and AKT, which prevents the activation of the PI3K-AKT-P70S6K signaling pathway, thereby inhibiting tumor cell proliferation (PMID: 27186432, PMID: 28376174).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PTEN loss||triple-receptor negative breast cancer||sensitive||M2698||Preclinical - Cell line xenograft||Actionable||In a preclinical study, a triple-receptor negative breast cancer xenograft model harboring PTEN loss was sensitive to M2698 (MSC2363318A), demonstrating inhibition of tumor growth and tumor regression (PMID: 27186432).||27186432|
|PIK3CA H1047R||breast cancer||sensitive||M2698||Preclinical - Cell line xenograft||Actionable||In a preclinical study, a breast cancer xenograft model harboring PIK3CA H1047R was sensitive to M2698 (MSC2363318A), demonstrating inhibition of tumor growth (PMID: 27186432).||27186432|
|PIK3CA mutant||Advanced Solid Tumor||sensitive||M2698||Preclinical||Actionable||In a preclinical study, MSC2363318A demonstrated anti-proliferative activity against many solid tumor cell lines with PI3K pathway genomic alterations, and inhibited tumor growth in several human cancer xenograft models of breast, pancreatic, glioblastoma and ovarian cancers (Mol Cancer Ther 2013;12(11 Suppl):A162).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT01971515||Phase I||M2698||First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies||Completed||USA||0|